{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:13:49Z","timestamp":1774548829107,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12882-016-0361-0","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T08:08:13Z","timestamp":1475827693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study"],"prefix":"10.1186","volume":"17","author":[{"given":"Mahesh R.","family":"Sigdel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukunda P.","family":"Kafle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dibya Singh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,7]]},"reference":[{"key":"361_CR1","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2010050472","volume":"21","author":"AS Bomback","year":"2010","unstructured":"Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010;21:2028\u201335.","journal-title":"J Am Soc Nephrol"},{"key":"361_CR2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"BH Hahn","year":"2012","unstructured":"Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797\u2013808.","journal-title":"Arthritis Care Res"},{"key":"361_CR3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"361_CR4","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"GK Bertsias","year":"2012","unstructured":"Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771\u201382.","journal-title":"Ann Rheum Dis"},{"key":"361_CR5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/sj.ki.5002663","volume":"73","author":"P Bhat","year":"2008","unstructured":"Bhat P, Radhakrishnan J. B lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapies. Kidney Int. 2008;73:261\u20138.","journal-title":"Kidney Int"},{"key":"361_CR6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","volume":"65","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, D\u2019Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521\u201330.","journal-title":"Kidney Int"},{"key":"361_CR7","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2:139\u2013274."},{"key":"361_CR8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/0961203308095330","volume":"18","author":"S Masood","year":"2009","unstructured":"Masood S, Jayne D, Karim Y. Beyond immunosuppression - challenges in the clinical management of lupus nephritis. Lupus. 2009;18:106\u201315.","journal-title":"Lupus"},{"key":"361_CR9","first-page":"9","volume":"23","author":"C Ponticelli","year":"2010","unstructured":"Ponticelli C, Glassock RJ, Moroni G. Induction and maintenance therapy in proliferative lupus nephritis. J Nephrol. 2010;23:9\u201316.","journal-title":"J Nephrol"},{"key":"361_CR10","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1056\/NEJM198412133112402","volume":"311","author":"DT Felson","year":"1984","unstructured":"Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med. 1984;311:1528\u201333.","journal-title":"N Engl J Med"},{"key":"361_CR11","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","volume":"314","author":"HA Austin 3rd","year":"1986","unstructured":"Austin 3rd HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614\u20139.","journal-title":"N Engl J Med"},{"key":"361_CR12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","volume":"125","author":"MF Gourley","year":"1996","unstructured":"Gourley MF, Austin 3rd HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125:549\u201357.","journal-title":"Ann Intern Med"},{"key":"361_CR13","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","volume":"46","author":"FA Houssiau","year":"2002","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121\u201331.","journal-title":"Arthritis Rheum"},{"key":"361_CR14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","volume":"350","author":"G Contreras","year":"2004","unstructured":"Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971\u201380.","journal-title":"N Engl J Med"},{"key":"361_CR15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61\u20134.","journal-title":"Ann Rheum Dis"},{"key":"361_CR16","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2215\/CJN.01200307","volume":"2","author":"M Walsh","year":"2007","unstructured":"Walsh M, James M, Jayne D, et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2007;2:968\u201375.","journal-title":"Clin J Am Soc Nephrol"},{"key":"361_CR17","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","volume":"343","author":"TM Chan","year":"2000","unstructured":"Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343:1156\u201362.","journal-title":"N Engl J Med"},{"key":"361_CR18","first-page":"705","volume":"115","author":"W Hu","year":"2002","unstructured":"Hu W, Liu Z, Chen H, et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl). 2002;115:705\u20139.","journal-title":"Chin Med J (Engl)"},{"key":"361_CR19","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219\u201328.","journal-title":"N Engl J Med"},{"key":"361_CR20","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1681\/ASN.2004080686","volume":"16","author":"TM Chan","year":"2005","unstructured":"Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16:1076\u201384.","journal-title":"J Am Soc Nephrol"},{"key":"361_CR21","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.","journal-title":"Arthritis Rheum"},{"key":"361_CR22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.mcna.2004.11.009","volume":"89","author":"LA Stevens","year":"2005","unstructured":"Stevens LA, Levey AS. Measurement of kidney function. Med Clin North Am. 2005;89:457\u201373.","journal-title":"Med Clin North Am"},{"key":"361_CR23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000087842","volume":"28","author":"L Tylicki","year":"2005","unstructured":"Tylicki L, Larczynski W, Rutkowski B. Renal protective effects of the renin-angiotensin-aldosterone system blockade: from evidence-based approach to perspectives. Kidney Blood Press Res. 2005;28:230\u201342.","journal-title":"Kidney Blood Press Res"},{"key":"361_CR24","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/rheumatology\/ken208","volume":"47","author":"S Duran-Barragan","year":"2008","unstructured":"Duran-Barragan S, McGwin Jr G, Vila LM, et al. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford). 2008;47:1093\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"361_CR25","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1440-1797.2010.01290.x","volume":"15","author":"OE Ayodele","year":"2010","unstructured":"Ayodele OE, Okpechi IG, Swanepoel CR. Predictors of poor renal outcome in patients with biopsy-proven lupus nephritis. Nephrology. 2010;15:482\u201390.","journal-title":"Nephrology"},{"key":"361_CR26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/j.ajkd.2010.08.036","volume":"57","author":"W Chen","year":"2011","unstructured":"Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis. 2011;57:235\u201344.","journal-title":"Am J Kidney Dis"},{"key":"361_CR27","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","volume":"73","author":"RF Vollenhoven van","year":"2014","unstructured":"van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73:958\u201367.","journal-title":"Ann Rheum Dis"},{"key":"361_CR28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1053\/j.ajkd.2010.10.052","volume":"57","author":"H Bagavant","year":"2011","unstructured":"Bagavant H, Kalantarinia K, Scindia Y, et al. Novel therapeutic approaches to lupus glomerulonephritis: translating animal models to clinical practice. Am J Kidney Dis. 2011;57:498\u2013507.","journal-title":"Am J Kidney Dis"},{"key":"361_CR29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5455\/apr.081820131500","volume":"2","author":"G Demircin","year":"2013","unstructured":"Demircin G. An Update on Treatment and Outcome of Lupus Nephritis in Children. Ann Paediatr Rheum. 2013;2:99\u2013106.","journal-title":"Ann Paediatr Rheum"},{"key":"361_CR30","first-page":"111","volume":"52","author":"BP Paudyal","year":"2012","unstructured":"Paudyal BP, Gyawalee M. Clinical profile of patients with systemic lupus erythematosus. JNMA J Nepal Med Assoc. 2012;52:111\u20137.","journal-title":"JNMA J Nepal Med Assoc"},{"key":"361_CR31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/ki.2009.136","volume":"76","author":"F Yu","year":"2009","unstructured":"Yu F, Tan Y, Liu G, et al. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int. 2009;76:307\u201317.","journal-title":"Kidney Int"},{"key":"361_CR32","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1136\/ard.2010.135186","volume":"69","author":"GK Bertsias","year":"2010","unstructured":"Bertsias GK, Salmon JE, Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis. 2010;69:1603\u201311.","journal-title":"Ann Rheum Dis"},{"key":"361_CR33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005792-199303000-00005","volume":"72","author":"R Cervera","year":"1993","unstructured":"Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72:113\u201324.","journal-title":"Medicine (Baltimore)"},{"key":"361_CR34","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/ndt\/gfr741","volume":"27","author":"SM Korbet","year":"2012","unstructured":"Korbet SM, Lewis EJ. Complete remission in severe lupus nephritis: assessing the rate of loss in proteinuria. Nephrol Dial Transplant. 2012;27:2813\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"361_CR35","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","volume":"69","author":"FA Houssiau","year":"2010","unstructured":"Houssiau FA, D\u2019Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69:2083\u20139.","journal-title":"Ann Rheum Dis"},{"key":"361_CR36","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","volume":"365","author":"MA Dooley","year":"2011","unstructured":"Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365:1886\u201395.","journal-title":"N Engl J Med"},{"key":"361_CR37","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1093\/ndt\/gfs179","volume":"27","author":"XW Yang","year":"2012","unstructured":"Yang XW, Tan Y, Yu F, et al. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transplant. 2012;27:3552\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"361_CR38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1681\/ASN.2006090992","volume":"18","author":"SM Korbet","year":"2007","unstructured":"Korbet SM, Schwartz MM, Evans J, et al. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18:244\u201354.","journal-title":"J Am Soc Nephrol"},{"key":"361_CR39","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ki.1994.70","volume":"45","author":"HA Austin 3rd","year":"1994","unstructured":"Austin 3rd HA, Boumpas DT, Vaughan EM, et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994;45:544\u201350.","journal-title":"Kidney Int"},{"key":"361_CR40","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1046\/j.1523-1755.2000.00293.x","volume":"58","author":"MM Schwartz","year":"2000","unstructured":"Schwartz MM. The Holy Grail: pathological indices in lupus nephritis. Kidney Int. 2000;58:1354\u20135.","journal-title":"Kidney Int"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-016-0361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T20:35:49Z","timestamp":1498336549000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-016-0361-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,7]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1186\/s12882-016-0361-0","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,7]]},"article-number":"145"}}